<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955318</url>
  </required_header>
  <id_info>
    <org_study_id>6500-003</org_study_id>
    <nct_id>NCT00955318</nct_id>
  </id_info>
  <brief_title>Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease</brief_title>
  <official_title>Phase 3 Study of KW-6500 (Safety Study for Long-Term Self-Administration at Home in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of KW-6500 when administered
      as long-term subcutaneous self-injections in Parkinson's disease patients with motor response
      complications on levodopa therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events after administration of KW-6500</measure>
    <time_frame>From first administration of study drug through Study Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to expression of the ON state, continuous time of the ON state, raw score change and percent score change in Unified Parkinson's Disease Rating Scale (UPDRS) part III, response ratio, and UPDRS part II score</measure>
    <time_frame>From first administration of study drug through Study Week 52</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>KW-6500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-6500</intervention_name>
    <description>Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state</description>
    <arm_group_label>KW-6500</arm_group_label>
    <other_name>Apomorphine hydroshloride (USAN)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have given written informed consent

          -  Patients who have Parkinson's disease

          -  Patients who have been on a stable regimen of levodopa plus at least one other
             antiparkinsonian agent and who have OFF state

          -  Patients who meet stage 4 or 5 while in the OFF state and stage 0 to 3 while in the ON
             state on the Modified Hoehn and Yahr Scale

          -  Patients who have experienced a 30% or more improvement in UPDRS partâ…¢ score when
             tested for responsiveness to levodopa during the baseline period

          -  Patients who have at least one OFF state per day

          -  Patients who can understand the expression of OFF state, ON state, and dyskinesia

          -  Patients or their families have a desire for self-injection of KW-6500

        Exclusion Criteria:

          -  Patients with an illness of the cardiac, hematologic, hepatic, renal, pancreatic,
             metabolic, respiratory, gastrointestinal, endocrinologic, or neurologic system
             (excluding Parkinson's disease)

          -  Patients with orthostatic hypotension

          -  Patients with a history of intolerance to morphine or its derivatives, sulfur,
             sulfur-containing pharmaceutical products, or sulfite

          -  Patients with a history of malignant syndrome

          -  Patients with a diagnosis of cancer or evidence of continued disease

          -  Patients who do not test negative in the direct Coombs' test

          -  Pregnant or lactating women, women who are planning to have children, women who test
             positive in the pregnancy test, or women who cannot adhere to a reliable method of
             contraception

          -  Patients who have received MAO inhibitors except selegiline

          -  Patients with a history of mental disease (excluding psychiatric symptoms associated
             with Parkinson's disease)

          -  Patients with a Mini-Mental State Examination (MMSE) score of 23 or less

          -  Patients who are taking antipsychotics or central dopamine antagonists (excluding
             domperidone)

          -  Patients who are receiving methyldopa or 5-HT3 receptor antagonists

          -  Patients who are receiving reserpine or papaverine

          -  Patients who have had a neurosurgical operation for Parkinson's disease

          -  Patients who have had transcranial magnetic stimulation

          -  Patients with a history of drug or alcohol abuse or dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

